Evidence map›Paper›PMID 36813998›Full record

ArticleEye (London, England)2023

Risk of retinal vein occlusion following COVID-19 vaccination: a self-controlled case series.

Marco Pellegrini, Adriano Carnevali, Tito Fiore, Carlo Cagini, Antonella De Palma, Luigi Fontana, Enrico Lupardi, Federico Cassini, Daniela Bacherini, Fabrizio Giansanti and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Marco PellegriniDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy. marco.pellegrini@hotmail.it.ORCID 0000-0002-6419-6941
Adriano CarnevaliDepartment of Ophthalmology, University Magna Græcia of Catanzaro, Catanzaro, Italy.
Tito FioreDepartment of Biomedical and Surgical Sciences, Section of Ophthalmology, S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
Carlo CaginiDepartment of Biomedical and Surgical Sciences, Section of Ophthalmology, S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.ORCID 0000-0002-3812-9219
Antonella De PalmaDepartment of Biomedical and Surgical Sciences, Section of Ophthalmology, S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
Luigi FontanaOphthalmology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Enrico LupardiOphthalmology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.ORCID 0000-0002-1344-9806
Federico CassiniOphthalmology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Daniela BacheriniEye Clinic, Neuromuscular and Sense Organs Department, Careggi University Hospital, Florence, Italy.
Fabrizio GiansantiEye Clinic, Neuromuscular and Sense Organs Department, Careggi University Hospital, Florence, Italy.
Giuseppe GiannaccareDepartment of Ophthalmology, University Magna Græcia of Catanzaro, Catanzaro, Italy.ORCID 0000-0003-2617-0289
Vincenzo ScorciaDepartment of Ophthalmology, University Magna Græcia of Catanzaro, Catanzaro, Italy.ORCID 0000-0001-6826-7957
Sabrina VaccaroDepartment of Ophthalmology, University Magna Græcia of Catanzaro, Catanzaro, Italy.
Nicolò CiarmatoriDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Sergio D'AngeloDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Francesco ParmeggianiDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.ORCID 0000-0002-9296-0986
Marco MuraDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
University of Ferrara · ITMagna Graecia University · ITAzienda USL di Bologna · ITUniversity of Perugia · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the association between COVID-19 vaccination and retinal vein occlusion (RVO).

methodsThis multicentre self-controlled case series included patients with RVO seen in five tertiary referral centres in Italy. All adults who received at least one dose of the BNT162b2, ChAdOx1 nCoV-19, mRNA-1273 or Ad26.COV2.S vaccine and had a first diagnosis of RVO between January 01, 2021, and December 31, 2021 were included. Incidence rate ratios (IRRs) of RVO were estimated using Poisson regression, comparing rates of events in a 28-day period following each dose of vaccination and in the unexposed control periods.

results210 patients were included in the study. No increased risk of RVO was observed after the first dose (1-14 days IRR: 0.87, 95% CI: 0.41-1.85; 15-28 days IRR: 1.01, 95% CI: 0.50-2.04; 1-28 days IRR: 0.94, 95% CI: 0.55-1.58) and second dose of vaccination (1-14 days IRR: 1.21, 95% CI: 0.62-2.37; 15-28 days IRR: 1.08, 95% CI: 0.53-2.20; 1-28 days IRR: 1.16, 95% CI: 0.70-1.90). No association between RVO and vaccination was found in subgroup analyses by type of vaccine, gender and age.

conclusionsThis self-controlled case series found no evidence of an association between RVO and COVID-19 vaccination.

Indexed as

COVID-19COVID-19 VaccinesRetinal Vein OcclusionAd26COVS1AdultBNT162 VaccineChAdOx1 nCoV-19HumansVaccinationAd26COVS1BNT162 VaccineChAdOx1 nCoV-19COVID-19 Vaccines

Identifiers

PMID36813998
PMCPMC9945824
OpenAlexW4321482992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.